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Abstract
Background: Studies on  Plasmodium falciparum  g a m e to cy te  d e ve lo pm e n t and dynam ics have 
a lm os t exc lus ive ly  focused on  pa tien ts  tre a te d  w ith  an tim a la ria l drugs, w h ile  th e  m a jo r ity  o f  parasite  
c a rr ie rs  in endem ic  areas are  asym p tom a tic . Th is  s tudy  iden tified  fa c to rs  th a t in fluence 
gam e tocy taem ia  in a sym p to m a tic  ch ild ren  in th e  absence and presence  o f  p y rim e th a m in e - 
su lphadox ine  (SP) a n tim a la ria l tre a tm e n t.
Methods: A  c o h o r t  o f  526 ch ild ren  (6 m on th s  -  16 years) fro m  w e s te rn  Kenya was screened fo r  
asexual parasites and gam e tocy tes  and fo llo w e d  w e e k ly  up t o  fo u r  w eeks. C h ild re n  w ith  an 
es tim a ted  parasitaem ia o f  > 1 ,000  p a ra s ite s /|il w e re  tre a te d  w ith  SP a cco rd ing  to  na tiona l guide lines.
Facto rs associated w ith  gam e to cy te  d e ve lo p m e n t and pe rs is tence  w e re  d e te rm in e d  in u n tre a te d  
and S P -trea ted  ch ild ren  w ith  P. falciparum  m o n o -in fe c tio n .
Results: G a m e to cy te  p reva lence  a t e n ro lm e n t was 33.8% in ch ild ren  b e lo w  five  years o f  age and 
decreased w ith  age. In th e  absence o f  tre a tm e n t 18.6% o f  th e  ch ild ren  deve loped  gam etocytaem ia  
d u rin g  fo llo w -u p ; in S P -trea ted  ch ild ren  th is  p ro p o r t io n  w as 29.8%. Age, high asexual parasite  
d ens ity  and ga m e to cy te  p resence a t e n ro lm e n t w e re  p re d ic tiv e  fa c to rs  fo r  gam etocytaem ia . T he  
e s tim a ted  mean d u ra tio n  o f  gam e tocy taem ia  fo r  ch ild ren  b e lo w  five, ch ild ren  fro m  five  t o  n ine and 
ch ild ren  te n  years and above was 9.4, 7 .8  and 4 .1  days, respective ly .
Conclusion: This s tudy  show s th a t a large p ro p o r t io n  o f  asym p to m a tic  u n tre a te d  ch ild ren  
d eve lop  gam etocytaem ia . G am e to cy ta e m ia  w as p a rtic u la r ly  co m m o n  in ch ild ren  b e lo w  five  years 
w h o  h a rb o r  gam e tocy tes  fo r  a lo n g e r p e rio d  o f  t im e . T he  age-dependent d u ra tio n  o f  
gam e tocy taem ia  has n o t been p re v io u s ly  show n and cou ld  increase th e  im p o rta n ce  o f  th is  age 
g ro u p  fo r  th e  in fec tious  re s e rv o ir .
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Background
The transmission of Plasmodium falciparum parasites from 
humans to mosquitoes requires the presence of infectious 
gametocytes in the hum an peripheral blood. The preva­
lence of gametocytes is, therefore, commonly used as a 
parameter of malaria transmission. Any strategy that inter­
feres with gametocyte development or persistence could 
result in a reduction of malaria transmission. For this pur­
pose, it is important to identify parameters that influence 
gametocyte development as well as gametocyte dynamics 
under natural conditions. Although the majority of para­
site carriers in endemic countries are asymptomatic [1], 
studies on gametocyte development and dynamics have 
almost exclusively focused on patients treated with anti- 
malarial drugs [2-11]. In these studies, gametocytaemia is 
influenced by the duration of symptoms [3,7], anaemia 
[4,7], type of antimalarial treatment response to
treatment [3,7,10] and age of infected individuals 
[6,8,11]. The relation between asexual parasites and 
gametocytes remains equivocal; a positive relation has 
been described between asexual parasite density at enrol­
m ent and gametocyte prevalence after treatment [6], but 
this was contradicted by several other studies [2-4].
This study describes the dynamics of gametocytaemia in a 
cohort of asymptomatic children naturally exposed to 
malaria in western Kenya. Children with microscopically 
detectable parasitaemia were observed longitudinally. 
Those developing parasitaemia at levels requiring antima- 
larial treatment were treated with the first line drug 
pyrimethamine-sulphadoxine (SP). This study identified 
factors associated with P. falciparum gametocyte produc­
tion in the absence or presence of SP-treatment. Within 
the group of gametocyte carriers, factors associated with 
gametocyte persistence were determined.
Methods
Study area and design
This five week study was conducted in October -  Novem­
ber 2001 in Mbita and Lwanda, small rural villages on the 
shores of Lake Victoria in Suba district, western Kenya. 
The transmission of P. falciparum is variable depending 
upon local environmental conditions that support mos­
quito populations. The entomological inoculation rate 
(EIR) was recently estimated at six infectious bites per per­
son per m onth [12]. Whilst variation in EIR may influence 
the clinical spectrum of malaria and gametocytaemia it is 
unlikely to be a factor in this short study. Data were col­
lected as described elsewhere [13]. Briefly, apparently 
healthy children (aged six months -  sixteen years) were 
recruited from primary schools and the community. 
Screening for asexual parasites and gametocytes of P. falci­
parum took place weekly for a period of five weeks. Finger 
prick blood samples were collected and thick blood 
smears were dried, stained with 10% Giemsa and exam­
ined microscopically. A slide was considered negative if 
no asexual parasites were seen after examination of 100 
fields. Gametocyte and asexual parasite densities were 
assessed by counting against 500 and 200 leukocytes, 
respectively, and converted to numbers of parasites per |il 
by assuming a standard leukocyte count of 8,000/ |il. Chil­
dren with a positive blood smear with an estimated para­
site density higher than 1,000 parasites/ |il on the initial or 
any subsequent visits were treated immediately with 
pyrimethamine-sulphadoxine (SP) according to national 
guidelines. Only children who were treated once in the 
first or second week of the study were included in the 
analyses to achieve a m inimum follow up period of three 
weeks. In case of treatment failure, alternative treatment 
was administered under supervision of the Clinical 
Officer. This resulted in the exclusion from the further 
study and follow-up.
Children or guardians signed an informed consent form. 
This study was approved by the ethical committee of the 
Kenya Medical Research Institute (KEMRI) and by the 
National Institute of Health (NIH) ethical review board of 
the United States.
Data analyses
Children who presented on at least three consecutive vis­
its were used for analyses. Those who reported the use of 
antimalarial drugs in the two weeks prior to enrolment or 
had a Plasmodium malariae mixed infection were excluded. 
The influence of age on transformed (natural logarithm) 
parasite densities was analysed in linear regression m od­
els. Discrete data were compared using chi-square or 
Fisher's exact test, trends in binary outcomes using the 
Cochran-Armitage test for trend. Predictive factors for 
gametocyte prevalence on days seven or fourteen were 
tested in non-treated and SP-treated children separately, 
using multiple regression models with SAS Generalized 
Estimating Equations (GEE). Presentation parasitaemia 
was included in the models as a continuous variable and 
non-parasitaemic children were excluded from the analy­
ses. A random effect was included in the models to allow 
for correlations within individuals. The Kaplan-Meier esti­
m ator was used to determine the proportion of parasitae- 
mic children developing gametocytaemia during the 
follow-up period. Only for this analysis, gametocyte carri­
ers at enrolment were excluded.
The duration of gametocytaemia in gametocyte carriers 
was estimated using the m ethod described by Drakeley et 
al. [14], assuming that a single gametocyte positive slide 
represented gametocytes circulating in the peripheral 
blood for at least 2.5 days [15]. When children had game- 
tocyte positive blood films on successive weeks, the esti­
mated duration of gametocytaemia was the interval 
between observations plus 2.5 days.
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Age N Asexual parasite 
prevalence, % (n)¥
Asexual parasite density, 
mean (IQR)t
Gametocyte prevalence
% (n)ïï
Gametocyte density 
mean (IQR)t
<5 years 65 73.8 (48) 2302.4 (530-14149) 33.8 (22) 25.3 (16-32)
5-9 years 211 50.2 (106) 357.8 (120-1040) 10.4 (22) 27.9 (16-32)
10-16 years 250 30.4 (76) 202.7 (80-440) 5.2 (13) 18.8 (16-23)
Total 526 43.7 (230) 444.8 (120-1220) 10.8 (57) 24.5 (16-32)
IQR = interquartile range ¥ Cochran-Armitage test for age-dependent trend in prevalence of asexual parasites (Z = -6.75, P < 0.001 ). t  Geometric 
mean of parasite carriers only (parasites/^l). Linear regression for log-transformed asexual parasite density and age groups, ß = -1.155; se(ß) = 
0.147, P < 0.001. ïï Cochran-Armitage test fo r age-dependent trend in prevalence of gametocytes (Z = -5.91, P < 0.001 ). t  Geometric mean of 
gametocyte carriers only (parasites/^l). Linear regression for log-transformed gametocyte density and age groups, ß = -0.123; se(ß) = 0.166, P = 
0.46.
Results
Gametocyte prevalence at enrolment was 33.8% (22/65) 
in children below five years of age and was negatively 
associated with age (table 1). Mean gametocyte density at 
enrolment was 24.5 (IQR 16-32) gametocytes/^l with no 
difference between age groups, whilst both asexual para­
site prevalence and density decreased with age. SP treat­
m ent was given to 27.2% (143/526) of the children who 
presented with asexual parasites on the first or second visit 
with a geometric mean density of 1,108.0 (IQR 249­
4235) parasites/^l. A group of 121 parasitaemic children 
exhibited relatively low parasitaemia at presentation (geo­
metric m ean density of 203.0 (IQR 80-400) parasites/^l) 
and was not given treatment throughout the study. The 
Kaplan-Meier estimator of time to gametocytaemia for 
these two groups of parasitaemic children is presented in 
figure 1. At the end of the four week follow-up period, the 
cumulative proportion of gametocytaemia was lower in 
children not receiving antimalarial treatment than in SP 
treated children, 18.6% and 29.8%, respectively. In both 
groups, gametocyte prevalence during the first two weeks 
of follow-up was independently associated with several 
factors (table 2). The risk for gametocytaemia during fol­
low-up was positively associated with asexual parasite 
density at enrolment and negatively with age. Children 
with detectable gametocytes at enrolment were more 
likely to show gametocytes during follow-up, after adjust­
m ent for age and asexual parasite density at the start of 
treatment. In children who received SP treatment, the 
probability of gametocyte prevalence seemed higher on 
day seven after treatment compared to day fourteen, 
although this was not statistically significant. R1 resist­
ance did not increase risk of gametocytes during follow- 
up while R2/R3 resistance did show such an association, 
OR 3.40 (95% CI 1.61-7.19). The estimated mean dura­
tion of gametocytaemia was 9.4 days (range 2.5 -  23.5) 
for children below five years of age, 7.8 days (range 2.5 -  
23.5) for children aged five to nine years and 4.1 days 
(range 2.5-16.5) for children aged ten years and above.
The duration of gametocytaemia was negatively associ­
ated with age (ß = -1.65, se(ß) = 0.73; p = 0.02), after 
adjustment for asexual parasite density and gametocyte 
density at enrolment. Treatment with SP did not inde­
pendently influence the duration of gametocytaemia.
Discussion
This descriptive study on the largely neglected group of 
asymptomatic children was part of a larger study on SP 
and gametocytes. A direct comparison between SP-treated 
and untreated children was not the aim of the current 
study and would require a different study design. SP- 
treated and untreated children differed with regards to 
treatment and asexual parasite density at enrolment and 
were therefore analysed separately.
In this study, 18.6% of the asymptomatic non-treated 
children developed gametocytaemia during a four week 
follow-up period. Gametocytaemia was particularly com­
m on in children <5 years of age, of whom one-third were 
already carrying gametocytes on enrolment. The high 
gametocyte prevalence in young children is in line with 
previous findings [6,11], although the longer duration of 
gametocytaemia for this age group has not been reported 
before. The age dependent duration of gametocytaemia 
could not be explained by asexual parasitaemia, gameto- 
cyte density or SP treatment, suggesting a role for age- 
dependent immune suppression of gametocytaemia. 
Acquired sexual stage specific immunity has previously 
been reported to influence gametocyte prevalence [16], 
but remains poorly defined. Although the exact duration 
of gametocytaemia could not be determined because of 
weekly intervals in data-collection, the longer estimated 
duration of gametocytaemia in the youngest age group 
combined with their higher gametocyte prevalence could 
increase the importance of this age group for the infec­
tious reservoir in this area. The importance of children as 
the infectious reservoir has been stressed elsewhere [17]. 
Differences in gametocytaemia during follow up should
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Figure!
The cumulative proportion of gametocytaemia in SP-treated and untreated children. K ap la n -M e ie r e s tim a to r  o f  
th e  t im e  to  gam e tocy taem ia  fo r  u n tre a te d  c h ild re n  (d o tte d  line ) and SP -treated ch ild ren  (so lid  line). G ro u p s  d iffe re d  in asexual 
parasite  den s ity  a t e n ro lm e n t. Patients w ith  in co m p le te  fo llo w -u p  are  m arked  o n  th e  curve . G a m e to cy te  c a rr ie rs  o n  day 0 
w e re  exc luded, as w e ll as ch ild ren  w h o  re p o r te d  th e  use o f  an tim a la ria l d rugs p r io r  to  e n ro lm e n t. L o g -rank  P = 0.05
be interpreted carefully since they are at least partially 
explained by differences in asexual parasite density at 
enrolment. The observed peak in gametocytaemia on day 
seven after SP treatment has been previously described [3­
6] and may include gametocytes circulating prior to treat­
m ent since seven days may be short for gametocytogene- 
sis, as was suggested by in vitro observations [18]. This 
study determined predictive factors for gametocytaemia 
for SP-treated and untreated children independently and 
found that risk factors were similar in both groups. Fur­
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Table 2: A d justed  odds ra tio  (OR) o f  the  p ro b a b ility  o f  gam etocyte  prevalence, using a m u ltiva r ia te  random  effect log istic m odel fo r  
un trea ted  and SP -treated ch ild ren  separately.
Risk factors for gametocytaemia Adjusted OR (95% CI)
No treatment Treatment with SP
Day of follow-up Day 7 1.48 (0.62 -  3.56)¥ I.77 (0.93-3.34)¥
Day I4 I (ref) I (ref)
Age <5 years 6.34 (I.I5-34.90) 5.38 ( I .9 I- I5 .I7 )
5-9 years 3.07 (0.98-9.55)¥ 3.22 ( i .I 9-8.72)
I0 - I6  years I (ref) I (ref)
Asexual parasite density at enrolment Per I00 parasites/^l 1.05 ( I .0 0 - I . I I ) 1.01 ( I.0 0 -I.0 I)
Gametocyte prevalence at enrolment Present 3.35 ( 1.22-9.18) 4.12 (2.I I - 8.02)
Absent I (ref) I (ref)
SP treatment outcome R2/3 resistance - 3.40 (1.61-7.19)
Rl resistance - 1.06 (0.45-2.47)¥
Adequate response - 1 (ref)
Adjusted = adjusted for all other variables in the model, OR = odds ratio, CI = confidence interval, ref = reference group, ¥ = not statistically 
significant, - = not applicable. A  GEE model was used to  allow for correlation between observations from the same individuals. Children reporting 
the use of antimalarial drugs prior to  enrolment were excluded from these analyses.
thermore, age and gametocyte presence at enrolment were 
previously described as predictors for gametocytaemia in 
symptomatic treated children [4,6-8,11]. Asexual parasi- 
taemia at enrolment was positively associated with game- 
tocytaemia during follow-up. Other studies [2-4] may not 
have found such an association because they only 
included patients with a high parasitaemia, resulting in 
little variation in asexual parasite density. Parasitological 
treatment failure was an im portant predictor of gametocy­
taemia in the SP-treated group [13].
Conclusions
This study shows that many asymptomatic children 
develop gametocytes, even in the absence of treatment. 
Gametocyte prevalence is especially high in children 
below five years of age who also appear to harbor gameto­
cytes for a longer period of time. Risk factors for gameto- 
cytaemia are similar to those described in symptomatic 
children and do not appear to differ between treated and 
untreated children.
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